HalioDx masters assay development on various technologies: immunohistochemistry, digital pathology, high throughput Next Generation Sequencing, quantitative PCR and nCounter® technology (Nanostring).
Depending on your project, our team can help you defining the adequate assay to support your research and scientific questions you might have.
HalioDx already developed several IHC on-demand tests that are now available in the portfolio like:
- NKp46*,
- Granzyme B,
- CD68,
- IDO,
- Ki67,
- MHC Class I,
- MHC Class II,
- CD25/FoxP3,
- etc…
* HalioDx proprietary assay
Poster presented at NHS 2017
This poster illustrates an example of HalioDx know-how using dedicated technologies developed in our laboratory.
As an example, 2 panels of biomarkers have been used to demonstrate the utility of multiplex technology that can be deployed for any panel of biomarkers our customers would like to test.
In this poster:
- Profiling immune contexture in tumor landscape for patients stratification and prediction of response to immunotherapies
- Determination of the Immune cells location in the tumor landscape
- Detection of multiple biomarkers on only 1 FFPE slide (Formalin-fixed paraffin embedded)
- Determination of complex phenotypes, cell densities and spatial distributions of cells in the tumor context.
